{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:55:46Z","timestamp":1787964946491,"version":"build-2784847793"},"reference-count":181,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU\/ml insulin glargine. There can also be concerns with different devices between the manufacturers.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold>To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.<\/jats:p><jats:p><jats:bold>Our approach:<\/jats:bold>Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU\/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU\/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold>There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities.<\/jats:p>","DOI":"10.3389\/fpubh.2021.671961","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:44:29Z","timestamp":1624524269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future"],"prefix":"10.3389","volume":"9","author":[{"given":"Brian","family":"Godman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mainul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Allocati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salequl","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaykaran","family":"Charan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanj","family":"Kurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vassalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Abu","family":"Bakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagir Abdur","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Deeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A. Halim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B. M. Muksudul","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iffat","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair Mahmood","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaira","family":"Hasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Munzur-E-Murshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsun","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monami","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jha Pallavi","family":"Abhayanand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimple Jeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey Mutashambara","family":"Rwegerera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Cristina Rezende Macedo do","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Piassi","family":"Dias God\u00f3i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adefolarin A.","family":"Amu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Matowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Acolatse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Incoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel Abebrese","family":"Sefah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Opanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisper Wangeci","family":"Njeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kimonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Young","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungJin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Koh Pek","family":"Khuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullahi Rabiu","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Haruna","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikria","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver Ombeva","family":"Malande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thereza","family":"Piloya-Were","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Gambogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hernandez Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Alutuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey Chichonyi","family":"Kalungia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Markovi\u0107-Pekovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Tubic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenka","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Tachkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ott","family":"Laius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Harsanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Inotai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianit","family":"Jakupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svens","family":"Henkuzens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Garuoliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Gulbinovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalene","family":"Wladysiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Mardare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurij","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McTaggart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"MacBride-Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caridad","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Twumwaa","family":"Tagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Banzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janney","family":"Wale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihajlo","family":"Jakovljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S2213-8587(17)30181-X","article-title":"Diabetes in sub-Saharan Africa: from clinical care to health policy","volume":"5","author":"Atun","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000459641","article-title":"The burden of diabetes: emerging data","volume":"60","author":"Maffi","year":"2017","journal-title":"Dev Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fphar.2020.00108","article-title":"Review of ongoing activities and challenges to improve the care of patients with type 2 diabetes across Africa and the implications for the future","volume":"11","author":"Godman","year":"2020","journal-title":"Front Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"107842","DOI":"10.1016\/j.diabres.2019.107842","article-title":"Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Patterson","year":"2019","journal-title":"Diabetes Res Clin Practice."},{"key":"B5","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.diabres.2020.108053","article-title":"The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives","volume":"161","author":"Ceriello","year":"2020","journal-title":"Diabetes Res Clin Practice."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2019029","DOI":"10.4178\/epih.e2019029","article-title":"Trends in the prevalence and management of diabetes in Korea: 2007-2017","volume":"41","author":"Shin","year":"2019","journal-title":"Epidemiol Health."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2224-3151.206546","article-title":"Diabetes in South-East Asia: burden, gaps, challenges and ways forward","volume":"5","author":"Roglic","year":"2016","journal-title":"WHO South East Asia J Public Health."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1186\/s12889-020-09502-x","article-title":"Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Pub Health."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(20)32374-6","article-title":"The lancet commission on diabetes: using data to transform diabetes care and patient lives","volume":"396","author":"Chan","year":"2021","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2337\/dc17-1962","article-title":"Global economic burden of diabetes in adults: projections from 2015 to 2030","volume":"41","author":"Bommer","year":"2018","journal-title":"Diabetes Care."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11892-019-1124-7","article-title":"Economic impact of diabetes in Africa","volume":"19","author":"Mapa-Tassou","year":"2019","journal-title":"Curr Diabetes Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00592-014-0698-4","article-title":"Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus","volume":"52","author":"Rys","year":"2015","journal-title":"Acta Diabetol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00592-014-0604-0","article-title":"The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials","volume":"52","author":"Dzyga\u0142o","year":"2015","journal-title":"Acta Diabetol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2213-8587(14)70073-7","article-title":"Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial","volume":"2","author":"Pedersen-Bjergaard","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"Cd005613","DOI":"10.1002\/14651858.CD005613.pub4","article-title":"(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus","volume":"11","author":"Semlitsch","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06642-7","article-title":"Comparative efficacy and safety of ultra-long-acting, long-acting, intermediate-acting, and biosimilar insulins for type 1 diabetes mellitus: a systematic review and network meta-analysis","author":"Tricco","year":"2021","journal-title":"J Gen Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0194801","DOI":"10.1371\/journal.pone.0194801","article-title":"Long-acting insulin analogues for type 1 diabetes: an overview of systematic reviews and meta-analysis of randomized controlled trials","volume":"13","author":"Laranjeira","year":"2018","journal-title":"PLoS ONE."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e001410","DOI":"10.1136\/bmjgh-2019-001410","article-title":"Insulin prices, availability and affordability in 13 low-income and middle-income countries","volume":"4","author":"Ewen","year":"2019","journal-title":"BMJ Glob Health."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2337\/dci18-0019","article-title":"Insulin access and affordability working group: conclusions and recommendations","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care."},{"key":"B20","unstructured":"National Essential Medicines List Committee (NEMLC) - Tertiary and Quaternary Level Essential Medicines List Reviewed Items2020"},{"key":"B21","unstructured":"$24 Billion Insulin Markets - Global Intelligence Database 2012-2018 & 2019-20232019"},{"key":"B22","unstructured":"Insulin Glargine Market: by Type (Pre-filled Syringe and Single Dose Vial), by Application (Type 1 Diabetes and Type 2 Diabetes), by Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy and Other Distribution Channels): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018\u201320252019"},{"key":"B23","unstructured":"Levemir"},{"key":"B24","unstructured":"Novo Nordisk 2018: Struggling Against the Tide2018"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s13300-020-00925-8","article-title":"The safety and efficacy of second-generation basal insulin analogues in adults with type 2 diabetes at risk of hypoglycemia and use in other special populations: a narrative review","volume":"11","author":"Cheng","year":"2020","journal-title":"Diabetes Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e000664","DOI":"10.1136\/bmjdrc-2019-000664","article-title":"Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK","volume":"7","author":"Thalange","year":"2019","journal-title":"BMJ Open."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s12325-020-01332-y","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine u300 in the Netherlands: evidence from a randomised controlled trial","volume":"37","author":"Evans","year":"2020","journal-title":"Adv Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12902-019-0460-6","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria","volume":"19","author":"Russel-Szymczyk","year":"2019","journal-title":"BMC Endocrine Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40258-013-0073-6","article-title":"Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review","volume":"12","author":"Caires de Souza","year":"2014","journal-title":"Appl Health Econ Health Policy."},{"key":"B30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40271-017-0291-3","article-title":"Quality of life of patients with type 1 diabetes mellitus using insulin analog glargine compared with NPH insulin: a systematic review and policy implications","volume":"11","author":"Almeida","year":"2018","journal-title":"Patient."},{"key":"B31","unstructured":"Model List of Essential Medicines2019"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e200075","DOI":"10.1590\/1980-549720200075","article-title":"Public financing of human insulins in Brazil: 2009-2017","volume":"23","author":"Dias","year":"2020","journal-title":"Rev Bras Epidemiol."},{"key":"B33","unstructured":"Suspensa Decis\u00e3o que Determinava Distribui\u00e7\u00e3o de An\u00e1logos de Insulina de Longa Dura\u00e7\u00e3o Pelo SUS2019"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jphsr\/rmab021","article-title":"A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine hagedorn insulin and the implications","volume":"20","author":"Almeida","year":"2021","journal-title":"J Pharm Health Serv Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21548331.2021.1906083","article-title":"Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications","volume":"28","author":"Haque","year":"2021","journal-title":"Hospital Practice."},{"key":"B36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.55320\/mjz.44.3.279","article-title":"Availability of essential antihypertensive and antidiabetic medicines in public health facilities in Lusaka district, Zambia","volume":"44","author":"Kalungia","year":"2017","journal-title":"Med J Zambia."},{"key":"B37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/21548331.2020.1745509","article-title":"Ongoing and planned activities to improve the management of patients with type 1 diabetes across Africa; implications for the future","volume":"48","author":"Godman","year":"2020","journal-title":"Hospital Practice."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0226169","DOI":"10.1371\/journal.pone.0226169","article-title":"Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia","volume":"14","author":"Kaiser","year":"2019","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11892-018-1003-7","article-title":"Type 1 diabetes in a resource-poor setting: malnutrition related, malnutrition modified, or just diabetes?","volume":"18","author":"Balcha","year":"2018","journal-title":"Curr Diabetes Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3389\/fphar.2019.01375","article-title":"The availability, pricing, and affordability of essential diabetes medicines in 17 low-, middle-, and high-income countries","volume":"10","author":"Babar","year":"2019","journal-title":"Front Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.36347\/sajp.2021.v10i04.002","article-title":"Assessing utilisation and expenditure on long-acting insulin analogues in kenya; findings and implications for the future","volume":"10","author":"Opanga","year":"2021","journal-title":"Sch Acad J Pharm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/bcp.14188","article-title":"Cost-effectiveness of long-acting insulin analogues vs. intermediate\/long-acting human insulin for type 1 diabetes: a population-based cohort followed over 10 years","volume":"86","author":"Lee","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"B43","first-page":"Sp265","article-title":"Costs associated with long-acting insulin analogues in patients with diabetes","volume":"24","author":"Alemayehu","year":"2018","journal-title":"Am J Manage Care."},{"key":"B44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13300-012-0018-3","article-title":"Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom","volume":"4","author":"Gordon","year":"2013","journal-title":"Diabetes Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/postgradmedj-2015-133716","article-title":"New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes","volume":"92","author":"Gururaj Setty","year":"2016","journal-title":"Postgrad Med J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jamainternmed.2020.0338","article-title":"Shift from adalimumab originator to biosimilars in Denmark","volume":"180","author":"Jensen","year":"2020","journal-title":"JAMA Internal Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1586\/14737167.2015.1085803","article-title":"Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe","volume":"15","author":"Matusewicz","year":"2015","journal-title":"Exp Rev Pharmacoeco Outcomes Res."},{"key":"B48","unstructured":"DavioK After Biosimilar Deals, UK Spending on Adalimumab Will Drop by 75%2018"},{"key":"B49","unstructured":"TyerD Biosimilars in the UK: Where Are We Now and Where Does the NHS Want to go?2019"},{"key":"B50","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamainternmed.2020.0331","article-title":"Decreasing health care spending through market competition-a case for the rapid adoption of adalimumab biosimilars","volume":"180","author":"Claytor","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7249\/PE264","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fphar.2019.01372","article-title":"The clinical implications of nocebo effects for biosimilar therapy","volume":"10","author":"Colloca","year":"2019","journal-title":"Front Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/psb.1781","article-title":"Why isn't the NHS making the most of biosimilar insulin?","volume":"30","author":"Greener","year":"2019","journal-title":"Prescriber."},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5639\/gabij.2020.0904.029","article-title":"Can local policies on biosimilars optimize the use of freed resources \u2013 experiences from Italy","volume":"9","author":"Godman","year":"2020","journal-title":"Gene Biosimilars Initiat J."},{"key":"B55","unstructured":"Medicines Update - Prescribing Medicines by Brand2020"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e023603","DOI":"10.1136\/bmjopen-2018-023603","article-title":"Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study","volume":"8","author":"Aladul","year":"2018","journal-title":"BMJ Open."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e016730","DOI":"10.1136\/bmjopen-2017-016730","article-title":"Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey","volume":"7","author":"Chapman","year":"2017","journal-title":"BMJ Open."},{"key":"B58","unstructured":"6.1.1 Insulins2020"},{"key":"B59","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1089\/dia.2017.0294","article-title":"Will biosimilar insulins be cheaper?","volume":"19","author":"Heinemann","year":"2017","journal-title":"Diabetes Technol Therap."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/dom.13291","article-title":"Biosimilar vs. originator insulins: systematic review and meta-analysis","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obesity Metab."},{"key":"B61","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.13904","article-title":"Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: results of the INSTRIDE 3 phase 3 switch study","volume":"22","author":"Blevins","year":"2020","journal-title":"Diabetes Obesity Metabo."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1007\/s12325-020-01436-5","article-title":"Reduced hypoglycemia risk in type 2 diabetes patients switched to\/initiating insulin glargine 300 vs","volume":"37","author":"Escalada","year":"2020","journal-title":"Adv Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00592-018-1258-0","article-title":"Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"56","author":"D\u00edez-Fern\u00e1ndez","year":"2019","journal-title":"Acta Diabetol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/dom.13105","article-title":"Better glycaemic control and less hypoglycaemia with insulin glargine 300 U\/mL vs glargine 100 U\/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes","volume":"20","author":"Ritzel","year":"2018","journal-title":"Diabetes Obesity Metab."},{"key":"B65","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jcjd.2019.04.012","article-title":"Real-world health outcomes of insulin glargine 300 U\/mL vs. insulin glargine 100 U\/mL in adults with type 1 and type 2 diabetes in the Canadian LMC diabetes patient registry: the reality study","volume":"43","author":"Abitbol","year":"2019","journal-title":"Canad J Diabetes."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2052101","DOI":"10.1155\/2018\/2052101","article-title":"Efficacy and safety of insulin glargine 300 U\/mL versus 100 U\/mL in diabetes mellitus: a comprehensive review of the literature","volume":"2018","author":"Vargas-Uricoechea","year":"2018","journal-title":"J Diabetes Res."},{"key":"B67","unstructured":"Insulin Glargine 300 Units\/mL Solution for Injection in a Pre-Filled Pen (Toujeo\u00ae)2015"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/dc19-2395","article-title":"Real-world budget impact of the adoption of insulin glargine biosimilars in primary care in England (2015-2018)","volume":"43","author":"Agirrezabal","year":"2020","journal-title":"Diabetes Care."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/17512433.2017.1371590","article-title":"Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications","volume":"10","author":"Mbui","year":"2017","journal-title":"Exp Rev Clin Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1605704","DOI":"10.1080\/16549716.2019.1605704","article-title":"Innovating to increase access to diabetes care in Kenya: an evaluation of Novo Nordisk's base of the pyramid project","volume":"12","author":"Shannon","year":"2019","journal-title":"Glob Health Action."},{"key":"B71","unstructured":"Sandoz- A Novartis Division Kenya is First Country to Launch \u2018Novartis Access\u2019, Expanding Affordable Treatment Options Against Chronic Diseases2015"},{"key":"B72","unstructured":"NdilwaL Reason to Smile for Diabetic Patients in Tanzania2020"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4134937","DOI":"10.1155\/2019\/4134937","article-title":"The burden of undiagnosed diabetes mellitus in adult African population: a systematic review and meta-analysis","volume":"2019","author":"Asmelash","year":"2019","journal-title":"J Diabetes Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.3389\/fendo.2021.606018","article-title":"Is misdiagnosis of type 1 diabetes mellitus in Malaysian children a common phenomenon?","volume":"12","author":"Mavinkurve","year":"2021","journal-title":"Front Endocrinol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12913-016-1946-9","article-title":"Selection of essential medicines for South Africa - an analysis of in-depth interviews with national essential medicines list committee members","volume":"17","author":"Perumal-Pillay","year":"2017","journal-title":"BMC Health Ser Res."},{"key":"B76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5639\/gabij.2019.0802.007","article-title":"Pricing of oral generic cancer medicines in 25 European countries; findings and implications","volume":"8","author":"Godman","year":"2019","journal-title":"Gene Biosimil Initiative J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","article-title":"Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart","year":"2019","journal-title":"Front Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40258-016-0272-z","article-title":"Inflammatory bowel diseases (Crohn's disease and ulcerative colitis): cost of treatment in serbia and the implications","volume":"15","author":"Kostic","year":"2017","journal-title":"Appl Health Econ Health Policy."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fphar.2020.591134","article-title":"The expiry of Humira \u00ae market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures","volume":"11","author":"Moorkens","year":"2021","journal-title":"Front Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5639\/gabij.2020.0904.027","article-title":"Local policies on biosimilars: are they designed to optimize use of liberated resources?","volume":"9","author":"Bertolani","year":"2020","journal-title":"Gener Biosimilars J."},{"key":"B82","unstructured":"Qu\u00e8 s\u00f3n els Medicaments Biosimilars?2020"},{"key":"B83","unstructured":"Secondary Care National Therapeutic Indicators 2019\/202019"},{"key":"B84","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1017\/S0266462319000138","article-title":"Assessing data sources for medicine price studies","volume":"35","author":"Vogler","year":"2019","journal-title":"Int J Technol Assess Health Care."},{"key":"B85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1586\/14737167.2016.1158649","article-title":"Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies","volume":"16","author":"Garuoliene","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3389\/fphar.2018.01156","article-title":"Antimicrobial medicines consumption in Eastern Europe and Central Asia \u2013 an updated cross-national study and assessment of quantitative metrics for policy action","volume":"9","author":"Robertson","year":"2019","journal-title":"Front Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s41669-017-0066-8","article-title":"Utilization and expenditure of anti-cancer medicines in kosovo: findings and implications","volume":"2","author":"Jakupi","year":"2018","journal-title":"PharmacoEconomics - Open."},{"key":"B88","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/ DDD Index"},{"key":"B89","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment2017"},{"key":"B90","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fphar.2010.00141","article-title":"Policies to enhance prescribing efficiency in Europe: findings and future implications","volume":"1","author":"Godman","year":"2010","journal-title":"Front Pharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fphar.2014.00219","article-title":"Different initiatives across Europe to enhance losartan utilization post generics: impact and implications","volume":"5","author":"Moon","year":"2014","journal-title":"Front Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/erp.11.42","article-title":"Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future","volume":"11","author":"Voncina","year":"2011","journal-title":"Exp Rev Pharmacoeco Outcomes Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1741-7015-12-98","article-title":"Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications","volume":"12","author":"Godman","year":"2014","journal-title":"BMC Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1586\/erp.10.72","article-title":"Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications","volume":"10","author":"Godman","year":"2010","journal-title":"Exp Rev Pharmacoeco Outcomes Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/14737167.2013.820956","article-title":"Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries","volume":"13","author":"Godman","year":"2013","journal-title":"Exp Rev Pharmacoeco Outcomes Res."},{"key":"B96","unstructured":"GDP per Capita (US$)2020"},{"key":"B97","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.3389\/fpubh.2020.585832","article-title":"Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future","volume":"8","author":"Godman","year":"2020","journal-title":"Front Public Health."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3389\/fphar.2020.582154","article-title":"Utilisation, availability and price changes of medicines and protection equipment for COVID-19 in India: findings and implications short title: COVID-19 and price changes of treatments in India","volume":"11","author":"Haque","year":"2021","journal-title":"Front Pharmacol."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3329\/bjms.v19i0.48106","article-title":"Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications","author":"Haque","year":"2020","journal-title":"Bangladesh J Med Sci."},{"key":"B100","unstructured":"Insulinas an\u00e1logas de a\u00e7\u00e3o prolongada para o tratamento de diabetes mellitus tipo I2018"},{"key":"B101","unstructured":"Ghana Standard Treatment Guidelines (2nd edition)2017"},{"key":"B102","doi-asserted-by":"publisher","first-page":"588106","DOI":"10.3389\/fphar.2020.588106","article-title":"Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus on Africa and the implications","volume":"11","author":"Sefah","year":"2021","journal-title":"Front Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fphar.2020.00970","article-title":"Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries?","volume":"11","author":"Kim","year":"2020","journal-title":"Front Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fphar.2020.00144","article-title":"Mapping of current obstacles for rationalizing use of medicines (CORUM) in Europe: current situation and potential solutions","volume":"11","author":"Gad","year":"2020","journal-title":"Front Pharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fphar.2020.00357","article-title":"Prospective risk assessment of medicine shortages in Europe and Israel: findings and implications","volume":"11","author":"Miljkovi\u0107","year":"2020","journal-title":"Front Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737167.2020.1734456","article-title":"Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries","volume":"20","author":"Godman","year":"2020","journal-title":"Expert Rev Pharmacoeco Outcomes Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/03007995.2019.1700947","article-title":"Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future","volume":"36","author":"Godman","year":"2020","journal-title":"Curr Med Res Opin."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e0190147","DOI":"10.1371\/journal.pone.0190147","article-title":"Policies for biosimilar uptake in Europe: an overview","volume":"12","author":"Moorkens","year":"2017","journal-title":"PLoS ONE."},{"key":"B109","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fmed.2020.00157","article-title":"Risks in antibiotic substitution following medicine shortage: a health-care failure mode and effect analysis of six European hospitals","volume":"7","author":"Miljkovi\u0107","year":"2020","journal-title":"Front Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12913-019-4829-z","article-title":"Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","volume":"19","author":"Mansell","year":"2019","journal-title":"BMC Health Serv Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5639\/gabij.2019.0803.014","article-title":"An ever-evolving landscape: an update on the rapidly changing regulation and reimbursement of biosimilars in Canada","volume":"8","author":"Siu","year":"2019","journal-title":"Gener Biosimilars Initiative J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5639\/gabij.2019.0803.012","article-title":"Ever-Evolving landscape of biosimilars in Canada; findings and implications from a global perspective","volume":"8","author":"Godman","year":"2019","journal-title":"Gener Biosimilars Initiative J."},{"key":"B113","unstructured":"Standard Treatment Guidelines and Essential Medicines List of Common Medical Conditions in the Kingdom of Swaziland2012"},{"key":"B114","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3389\/fphar.2017.00751","article-title":"Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa; a preliminary study","volume":"8","author":"Meyer","year":"2017","journal-title":"Front Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e0245036","DOI":"10.1371\/journal.pone.0245036","article-title":"Appropriateness and affordability of prescriptions to diabetic patients attending a tertiary hospital in Eastern Uganda: a retrospective cross-sectional study","volume":"16","author":"Obakiro","year":"2021","journal-title":"PLoS ONE."},{"key":"B116","unstructured":"Ghana National Drugs Programme (GNDP) - Essential Medicines List. 7th Edition2017"},{"key":"B117","unstructured":"Diabetes: Novo Nordisk to Offer Free Insulin to Children in Nigeria, Ghana2020"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1611243","DOI":"10.1080\/16549716.2019.1611243","article-title":"Challenges in policy reforms for non-communicable diseases: the case of diabetes in Kenya","volume":"12","author":"Shiroya","year":"2019","journal-title":"Glob Health Action."},{"key":"B119","unstructured":"Kenya National Strategy for the Prevention and Control of Non-Communicable Diseases 2015-20222015"},{"key":"B120","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/hpm.2905","article-title":"Patient costs of diabetes mellitus care in public health care facilities in Kenya","volume":"35","author":"Oyando","year":"2020","journal-title":"Int J Health Plann Manage."},{"key":"B121","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.vhri.2020.05.005","article-title":"Knowledge and attitude of physicians towards the cost of commonly prescribed medicines: a case study in three Nigerian healthcare facilities","volume":"22","author":"Fadare","year":"2020","journal-title":"Value Health Region Issues."},{"key":"B122","doi-asserted-by":"publisher","first-page":"798","DOI":"10.15171\/ijhpm.2018.19","article-title":"Out-of-pocket payments, catastrophic health expenditure and poverty among households in Nigeria 2010","volume":"7","author":"Aregbeshola","year":"2018","journal-title":"Int J Health Policy Manage."},{"key":"B123","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1586\/14737167.2016.1120673","article-title":"The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians","volume":"16","author":"Fadare","year":"2016","journal-title":"Exp Rev Pharmacoeco Outcomes Res."},{"key":"B124","unstructured":"IDF Ninth Edition - Country Summary Table2019"},{"key":"B125","unstructured":"Portaria 19 de 27 de mar\u00e7o de 2019. Torna p\u00fablica a decis\u00e3o de incorporar insulina an\u00e1loga de a\u00e7\u00e3o prolongada para o tratamento de diabetes mellitus tipo I, no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS2019"},{"key":"B126","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s13300-016-0166-y","article-title":"Clinical effectiveness and safety of analog glargine in type 1 diabetes: a systematic review and meta-analysis","volume":"7","author":"Marra","year":"2016","journal-title":"Diabetes Ther."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e0227565","DOI":"10.1371\/journal.pone.0227565","article-title":"Disease-specific out-of-pocket healthcare expenditure in urban Bangladesh: a Bayesian analysis","volume":"15","author":"Rahman","year":"2020","journal-title":"PLoS ONE."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/heapol\/czx048","article-title":"Catastrophic healthcare expenditure and poverty related to out-of-pocket payments for healthcare in Bangladesh-an estimation of financial risk protection of universal health coverage","volume":"32","author":"Khan","year":"2017","journal-title":"Health Policy Plan."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e000033","DOI":"10.1136\/bmjgh-2016-000033","article-title":"Healthcare use and expenditure for diabetes in Bangladesh","volume":"2","author":"Shariful Islam","year":"2017","journal-title":"BMJ Global Health."},{"key":"B130","doi-asserted-by":"crossref","unstructured":"SoodN WagnerZ JAMA Health Forum. India's Historic Effort to Expand Health Insurance to Individuals Living Below the Poverty Line2020","DOI":"10.1001\/jamahealthforum.2020.0229"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1001\/jama.2018.5284","article-title":"Health care reforms in India","volume":"319","author":"Reddy","year":"2018","journal-title":"JAMA."},{"key":"B132","unstructured":"Updates of the NHIS Drug List for Reimbursement2020"},{"key":"B133","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40258-017-0307-0","article-title":"Drug pricing in South Korea","volume":"15","author":"Kwon","year":"2017","journal-title":"Appl Health Econ Health Policy."},{"key":"B134","unstructured":"Malaysia's Government Procurement Regime2010"},{"key":"B135","unstructured":"SinghS Biocon's Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification2019"},{"key":"B136","unstructured":"Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia2017"},{"key":"B137","unstructured":"Biocon Wins Three-Year Contract to Supply Insulin in Malaysia2017"},{"key":"B138","unstructured":"AyubI Pakistan Among Top 10 Countries in Prevalence of Diabetes2019"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e034720","DOI":"10.1136\/bmjopen-2019-034720","article-title":"Impact of national drug pricing policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post survey study using WHO\/HAI methodology","volume":"10","author":"Saeed","year":"2020","journal-title":"BMJ Open."},{"key":"B140","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12939-018-0906-x","article-title":"Assessing the relationship between out-of-pocket spending on blood pressure and diabetes medication and household catastrophic health expenditure: evidence from Pakistan","volume":"18","author":"Datta","year":"2019","journal-title":"Int J Equity Health."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e0216122","DOI":"10.1371\/journal.pone.0216122","article-title":"Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: a cross-sectional survey using WHO\/HAI methodology","volume":"14","author":"Saeed","year":"2019","journal-title":"PLoS ONE."},{"key":"B142","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5639\/gabij.2016.0504.041","article-title":"Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for the future","volume":"5","author":"Khan","year":"2016","journal-title":"Generi Biosimilars Initiative J."},{"key":"B143","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(15)00521-5","article-title":"Constraints and challenges in access to insulin: a global perspective","volume":"4","author":"Beran","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B144","unstructured":"Country Scorecards for Biosimilar Sustainability2020"},{"key":"B145","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fphar.2017.00288","article-title":"Pricing and reimbursement of biosimilars in Central and Eastern European countries","volume":"8","author":"Kawalec","year":"2017","journal-title":"Front Pharmacol."},{"key":"B146","unstructured":"SinghV Top Biosimilar Companies with Approved and Pipeline Products in the US and EU2019"},{"key":"B147","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14737167.2018.1501558","article-title":"Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications","volume":"18","author":"Leporowski","year":"2018","journal-title":"Exp Rev Pharmacoeco Outcomes Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2217\/cer-2018-0132","article-title":"Ongoing initiatives within the Scottish national health service to affect the prescribing of selective serotonin reuptake inhibitors and their influence","volume":"8","author":"Godman","year":"2019","journal-title":"J Compar Effect Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5639\/gabij.2018.0704.030","article-title":"Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish national health service: their effect and implications","volume":"7","author":"Godman","year":"2018","journal-title":"Gener Biosimilars Initiative J."},{"key":"B150","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00125-020-05375-2","article-title":"A global perspective on the issue of access to insulin","volume":"64","author":"Beran","year":"2021","journal-title":"Diabetologia."},{"key":"B151","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/dme.13947","article-title":"A perspective on global access to insulin: a descriptive study of the market, trade flows and prices","volume":"36","author":"Beran","year":"2019","journal-title":"Diabetic Med."},{"key":"B152","unstructured":"WHO Launches First-Ever Insulin Prequalification Programme to Expand Access to Life-Saving Treatment for Diabetes2019"},{"key":"B153","unstructured":"Biosimilars - Insulins2021"},{"key":"B154","unstructured":"East African Community COVID-19 Response Plan2020"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fphar.2020.01205","article-title":"Response to the novel corona virus (COVID-19) pandemic across Africa: successes, challenges, and implications for the future","volume":"11","author":"Ogunleye","year":"2020","journal-title":"Front Pharmacol."},{"key":"B156","unstructured":"KewJ Aspen Pharmacare to Deliver J&J Vaccines in Next Three Months2021"},{"key":"B157","unstructured":"Technology Transfer by Ukrainian Company for Recombinant Human Insulin Production in Farmanguinhos2015"},{"key":"B158","doi-asserted-by":"publisher","first-page":"e000850","DOI":"10.1136\/bmjgh-2018-000850","article-title":"Production costs and potential prices for biosimilars of human insulin and insulin analogues","volume":"3","author":"Gotham","year":"2018","journal-title":"BMJ Global Health."},{"key":"B159","unstructured":"IQVIA Report 2018: The Impact of Biosimilar Competition in Europe"},{"key":"B160","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","article-title":"The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases","volume":"80","author":"Kim","year":"2020","journal-title":"Drugs."},{"key":"B161","unstructured":"Biosimilar Medicines: A National Prescribing Framework2018"},{"key":"B162","doi-asserted-by":"crossref","unstructured":"Secondary Care National Therapeutic Indicators 2018\/19","DOI":"10.1097\/PCC.0000000000001652"},{"key":"B163","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/jrpp.JRPP_18_74","article-title":"Empowering hypertensive patients in south africa to improve their disease management: a pharmacist-led intervention","volume":"8","author":"Rampamba","year":"2019","journal-title":"J Res Pharm Pract."},{"key":"B164","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jphs.12283","article-title":"Knowledge regarding medicines management of type-2 diabetes among patients attending a community health centre in South Africa","volume":"10","author":"Moosa","year":"2019","journal-title":"J Pharm Health Serv Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/17476348.2019.1624528","article-title":"Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications","volume":"13","author":"McCabe","year":"2019","journal-title":"Exp Rev Respir Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s41669-019-0172-x","article-title":"Impact of a clinical pharmacist intervention on medicine costs in patients with chronic obstructive pulmonary disease in India","volume":"4","author":"Abdulsalim","year":"2020","journal-title":"PharmacoEconomics - Open."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s13300-017-0315-y","article-title":"A randomized controlled trial to assess the impact of proper insulin injection technique training on glycemic control","volume":"8","author":"Misnikova","year":"2017","journal-title":"Diabetes Ther."},{"key":"B168","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40258-013-0059-4","article-title":"Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries","volume":"11","author":"Hesse","year":"2013","journal-title":"Appl Health Econ Health Policy."},{"key":"B169","volume-title":"WHO Guideline on Country Pharmaceutical Pricing Policies, second edition","year":"2020"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2399202619852317","article-title":"Emerging voluntary cooperation between European healthcare systems: are we facing a new future?","author":"Eatwell","year":"2019","journal-title":"Medicine."},{"key":"B171","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40273-019-00781-w","article-title":"Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?","volume":"37","author":"O'Mahony","year":"2019","journal-title":"PharmacoEconomics."},{"key":"B172","unstructured":"Defining Value in \u201cValue Based Healthcare\u201d Report of the Expert Panel on Effective Ways of Investing in Health (EXPH)2019"},{"key":"B173","doi-asserted-by":"publisher","first-page":"50338","DOI":"10.3329\/bjms.v20i1.50338","article-title":"Biosimilars are becoming indispensable in the management of multiple diseases although concerns still exist","volume":"20","author":"Godman","year":"2021","journal-title":"Bangladesh J Med Sci."},{"key":"B174","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bcpt.12295","article-title":"Quality indicators as a tool in improving the introduction of new medicines","volume":"116","author":"Campbell","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2296-12-85","article-title":"Framework and indicator testing protocol for developing and piloting quality indicators for the UK quality and outcomes framework","volume":"12","author":"Campbell","year":"2011","journal-title":"BMC Fam Pract."},{"key":"B176","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.healthpol.2009.09.014","article-title":"Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment","volume":"94","author":"Wettermark","year":"2010","journal-title":"Health Policy."},{"key":"B177","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1586\/erp.10.87","article-title":"Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs","volume":"11","author":"Godman","year":"2011","journal-title":"Exp Rev Pharmacoecon Outcomes Res."},{"key":"B178","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1586\/14787210.2015.990381","article-title":"The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications","volume":"13","author":"Furst","year":"2015","journal-title":"Exp Rev Anti-Infect Ther."},{"key":"B179","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/11585970-000000000-00000","article-title":"Does the market share of generic medicines influence the price level?","volume":"29","author":"Dylst","year":"2011","journal-title":"PharmacoEconomics."},{"key":"B180","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2217\/cer.12.52","article-title":"Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications","volume":"1","author":"Woerkom","year":"2012","journal-title":"J Compar Effect Res."},{"key":"B181","unstructured":"Changing the Game to Improve Availability and Affordability of Quality-Assured Insulin and Associated Devices2020"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.671961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T08:13:52Z","timestamp":1699172032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.671961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":181,"alternative-id":["10.3389\/fpubh.2021.671961"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.671961","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"article-number":"671961"}}